ID   RPMI-8226-R
AC   CVCL_XK17
SY   RPMI 8226-R; RPMI 8226R
DR   cancercelllines; CVCL_XK17
DR   PRIDE; PXD013859
DR   Wikidata; Q98129177
RX   PubMed=31465861;
CC   Population: African American.
CC   Characteristics: Produces IgG lambda (from parent cell line).
CC   Selected for resistance to: ChEBI; CHEBI:52717; Bortezomib (Velcade).
CC   Sequence variation: Gene fusion; HGNC; 5722; IGKJ4 + HGNC; 5783; IGKV2-28; Name(s)=IGKV2-28-IGKJ4 (from parent cell line).
CC   Sequence variation: Gene fusion; HGNC; 5865; IGLJ3 + HGNC; 5888; IGLV2-14; Name(s)=IGLV2-14-IGLJ3 (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Thr751Ile (c.2252C>T); ClinVar=VCV000177773; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ala (c.35G>C); ClinVar=VCV000045122; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu285Lys (c.853G>A); ClinVar=VCV000420133; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 12033; TRAF3; Simple; p.Lys191Leufs*60; Zygosity=Unspecified (from parent cell line).
CC   Omics: Deep quantitative proteome analysis.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
CC   Cell type: B-cell; CL=CL_0000236.
DI   NCIt; C3242; Plasma cell myeloma
DI   ORDO; Orphanet_29073; Multiple myeloma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0014 ! RPMI-8226
SX   Male
AG   61Y
CA   Cancer cell line
DT   Created: 19-12-19; Last updated: 05-10-23; Version: 8
//
RX   PubMed=31465861; DOI=10.1016/j.jprot.2019.103504;
RA   Chanukuppa V., Paul D., Taunk K., Chatterjee T., Sharma S., Kumar S.,
RA   Santra M.K., Rapole S.;
RT   "XPO1 is a critical player for bortezomib resistance in multiple
RT   myeloma: a quantitative proteomic approach.";
RL   J. Proteomics 209:103504.1-103504.10(2019).
//